Overview

A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1

Status:
Completed
Trial end date:
2021-05-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC